



Vicente Anido, Jr. nominated for election to Nicox's Board of Directors

April 26, 2013.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) today announced that the Company's Board of Directors has nominated Vicente Anido, Jr., PhD., to be elected to the Board. Dr. Anido is a highly respected and experienced leader in the ophthalmology sector. He most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb. The election of Dr. Anido to Nicox's Board will be voted on at the Company's 2013 Ordinary Shareholder Meeting, which will be convened for June 6, 2013.

"The Board is pleased to propose Vince Anido as a Board member of Nicox. Vince has a wealth of experience in the management of pharmaceutical companies, particularly in the ophthalmic area. We believe he would be a significant addition to the existing strength and combined experience of the Nicox Board as we work towards building an international ophthalmology business," said **Michele Garufi, Chief Executive Officer of Nicox.**

About Vicente Anido, Jr.

From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a Director of ISTA Pharmaceuticals, a US-based ophthalmic pharmaceutical company. Prior to this, he was general partner of Windamere Venture Partners, served as President and CEO of CombiChem, Inc., a biotechnology company, and was President of the Americas Region of Allergan, a specialty pharmaceutical company focusing on ophthalmology, dermatology and neuromuscular indications.

Dr. Anido currently serves on the Board of Directors of QLT Inc. and Depomed Inc., two NASDAQ-listed pharmaceutical companies, and was recently named Chairman of the Board of Directors of Aerie Pharmaceuticals, a US private ophthalmic company.


Dr. Anido received a B.S. in Pharmacy, an M.S. in Pharmacy Administration from West Virginia University

and a Ph.D. in Pharmacy Administration from the University of Missouri.

Information on the 2013 Ordinary Shareholder Meeting is available on the Nicox internet website:

<http://www.nicox.com/index.php/en/investor-information/shareholder-meetings>.

.....



About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sized international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus™, a test for the differential diagnosis of acute conjunctivitis licensed from RPS®.

The Company's pipeline includes latanoprostene bunod, a novel drug candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada) and Ferrer.


Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Small Caps). For more information please visit www.nicox.com.

.....

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

.....



Nicox Contacts

Nicox	Gavin Spencer Executive Vice President Corporate Development Tel +33 (0)4 97 24 53 00 communications@nicox.com
Media Relations	FTI Consulting
Europe	Jonathan Birt D+44 (0)20 7269 7205 M +44 (0) 7515 597 858 Jonathan.Birt@fticonsulting.com Stephanie Cuthbert D +44 (0)20 3077 0458 M +44 (0) 7843 080947 Stephanie.Cuthbert@fticonsulting.com